HER2 positivity was significantly associated with Lauren intestinal subtype (100% versus 68.5%, p = 0.010), low-grade tumours, defined as G1–G2, (92.9% versus, 55.4%, p = 0.008) and less deep tumour invasion, defined as T1–T2 (71.4% versus 35.9%, p = 0.018), with no significant difference in lymph node involvement (64.3% versus 53.3%, p = 0.568). Here, ERBB2 is linked to neoplasm.